Mosaiques Diagnostics GmbH, Hannover, Germany.
Proteomics Clin Appl. 2011 Jun;5(5-6):256-68. doi: 10.1002/prca.201000133. Epub 2011 May 18.
To date, multiple biomarker discovery studies in urine have been conducted. Nevertheless, the rate of progression of these biomarkers to qualification and even more clinical application is extremely low. The scope of this article is to provide an overview of main clinically relevant proteomic findings from urine focusing on kidney diseases, bladder and prostate cancers. In addition, approaches for promoting the use of urine in clinical proteomics including potential means to facilitate the validation of existing promising findings (biomarker candidates identified from previous studies) and to increase the chances for success for the identification of new biomarkers are discussed.
迄今为止，已经进行了多项尿液生物标志物发现研究。然而，这些生物标志物的进展速度极低，甚至无法达到合格标准，更无法应用于临床。本文的范围是提供尿液中与肾脏疾病、膀胱癌和前列腺癌相关的主要临床相关蛋白质组学发现的概述。此外，还讨论了促进尿液在临床蛋白质组学中的应用的方法，包括促进现有有前途的发现（从前瞻性研究中确定的生物标志物候选物）验证的潜在手段，并增加识别新生物标志物的成功机会。
